| http://www.w3.org/ns/prov#value | - As there is no standard of care for patients with MF/SS requiring systemic chemotherapy and the decision to initiate therapy is individualized, including consideration of responses and complications related to prior therapies, participation in a well-designed clinical trial is always worth consideration.High-dose chemotherapy and hematopoietic stem cell transplantationThe available experience with
|
